Regeneron Acquires 23andMe Assets for $256 Million Post-Bankruptcy

Regeneron Pharmaceuticals has acquired the majority of assets from 23andMe for $256 million following the company’s bankruptcy, aiming to enhance its genetics-based drug discovery efforts while prioritizing customer data privacy and security.
View full story…